Experience with the clinical development of influenza vaccines for potential pandemics

J. M. Wood*, K. G. Nicholson, I. Stephenson, Maria Zambon, R. W. Newman, D. L. Major, A. Podda

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    9 Citations (Scopus)

    Abstract

    During normal interpandemic influenza seasons, immune responses to vaccines are quite predictable and meet the licensing criteria of the European Union (EU) Committee for Proprietary Medicinal Products (CPMP). In a pandemic situation, large sections, if not all of the community will be immunologically naïve and therefore new immunisation strategies will be needed. In 1976 and 1977 H1N1 vaccines were prepared and tested clinically. To stimulate 'protective' antibody responses, two doses of vaccine were needed in people below the age of 24 years (no previous experience of H1N1 virus), whereas one conventional dose was adequate in older people. In 1997, the highly pathogenic avian influenza H5N1 virus caused widespread concern when it infected man, with lethal effects. Due to safety concerns it was necessary to adopt new strategies for vaccine development and one such strategy was to produce vaccine from an avirulent H5N3 virus, A/Duck/Singapore-Q/F119-2/97. Clinical trials of a subunit vaccine prepared from A/Duck/Sing/97 virus revealed that even two doses of twice the normal vaccine concentration (i.e. 30 μg haemagglutinin) were poorly immunogenic, whereas an H5N3 vaccine adjuvanted with microfluidised emulsion (MF) 59 stimulated antibody levels that complied with CPMP criteria after two half strength doses (i.e. 7.5 μg haemagglutinin).

    Original languageEnglish
    Pages (from-to)197-201
    Number of pages5
    JournalMedical Microbiology and Immunology
    Volume191
    Issue number3-4
    DOIs
    Publication statusPublished - 2002

    Keywords

    • Influenza
    • Pandemic
    • Vaccine

    Fingerprint

    Dive into the research topics of 'Experience with the clinical development of influenza vaccines for potential pandemics'. Together they form a unique fingerprint.

    Cite this